Bristol-Myers Squibb Co vs Consumer Staples Select Sector SPDR Fund — how do they compare? Bristol-Myers Squibb Co trades at $58.34 (market cap $116.30B), while Consumer Staples Select Sector SPDR Fund trades at $83.83. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Consumer Staples Select Sector SPDR Fund pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| BMY | XLP | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $90.00 |
52-Week Low | $42.60 | $75.61 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $84.58, up 0.55% with a bullish technical signal from moving averages. The ETF holds 36 consumer staples stocks and offers a 2.6% dividend yield. Analyst consensus is strongly positive with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid market uncertainty, with retail sales hitting 12-month highs supporting the sector.
XLP presents a defensive investment opportunity with stable dividend income and low volatility characteristics. The fund's concentrated portfolio of essential consumer goods companies provides resilience during market downturns. Key risks include sector rotation away from defensive stocks and potential margin pressure from inflation. Current technical strength and positive analyst sentiment support near-term upside potential.
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →